Screener
Nurix Therapeutics, Inc. NRIX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | Three Months Ended May 31, 2026 | Three Months Ended May 31, 2025 | Six Months Ended May 31, 2026 | Six Months Ended May 31, 2025 |
|---|---|---|---|---|
| Numerator: | ||||
| Net loss | $(89,535) | $(43,464) | $(176,709) | $(99,815) |
| Denominator: | ||||
| Weighted-average number of shares outstanding, basic and diluted(1) | 111,084,423 | 83,882,477 | 110,583,610 | 83,723,403 |
| Net loss per share, basic and diluted | $(0.81) | $(0.52) | $(1.60) | $(1.19) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s EPS (basic)?
- Nurix Therapeutics, Inc. (NRIX) reported EPS (basic) of -$0.81 in Q1 2026.
- How has Nurix Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Nurix Therapeutics, Inc.'s EPS (basic) decreased by 55.8% year-over-year, from -$0.52 to -$0.81.
- What is the long-term trend for Nurix Therapeutics, Inc.'s EPS (basic)?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s EPS (basic) has grown at a 2.8% compound annual growth rate (CAGR), from -$2.73 to -$3.05.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Nurix Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude